Focused on the evaluation of strategic alternatives Adopted a restructuring plan to extend capital resources, incurring a reduction in workforce of 30% to support the evaluation of strategic options and the Phase 1 study for LAVA-1266 Phase 1 enrollment in LAVA-1266 clinical trial underway Johnson and Johnson development milestone of $5.0 million achieved and received

Ysios Capital

01.04.2025

Mineralys Therapeutics Late-Breaking Data from Advance-HTN Pivotal Trial – Ysios Capital

Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted reduction (p=0.001), assessed by 24hr ABPM at week 12, with favorable safety and tolerability profile Lorundrostat is a highly selective aldosterone synthase inhibitor that disrupts aldosterone biosynthesis rather than blocking the mineralocorticoid receptor Data from Advance-HTN support the potential of lorundrostat

Ysios Capital

02.04.2025

Adcendo Strengthens Executive Leadership Team – Ysios Capital

Adcendo ApS Announces Changes in Board of Directors and Strengthens Executive Leadership Team

home›Ysios Capital

Ysios Capital

Startups

Mineralys Therapeutics to Host KOL Call– Ysios Capital

– Ysios Capital

Mineralys Therapeutics Late-Breaking Data from Advance-HTN Pivotal Trial – Ysios Capital

Adcendo Strengthens Executive Leadership Team – Ysios Capital

home
›
Ysios Capital